Private equity firm taps ex-Editas CEO Jim Mullen to help expand pharma portfolio — with a nod to cell, gene therapies
2023-03-28
并购高管变更
Jim Mullen is lending his years of biotech CEO experience — from Biogen, Patheon and Editas — to the private equity firm Advent International.
Advent managing partner John Maldonado said Mullen will help his team expand their reach to pharmaceutical and pharma services companies “across contract manufacturing, commercialization, and research.”
“Jim’s work at Editas and Thermo Fisher have put him at the forefront of the cell and gene therapy revolution,” Carmine Petrone, managing director at Advent, added in a statement. “We are excited to partner with Jim as we continue to look for transformative companies that are enabling the development, manufacture and commercialization of these advanced therapies.”
As an
operating partner
, Mullen joins more than 125 industry executives as independent advisors to Advent and its portfolio companies.
Mullen was perhaps best known as the former CEO of Biogen, who presided over its merger with Idec in 2003 and the growth of its multiple sclerosis franchise — but was ultimately pushed out by activist investors.
After leaving Biogen, he took up the CEO role at contract development and manufacturing organization Patheon, which was sold to Thermo Fisher
for $7.2 billion
in 2017. He also
briefly served as CEO
of gene editing pioneer Editas, where he
remains chairman
.
In May, Advent closed its 10th fund with $25 billion raised. Other than healthcare, the firm also invests in business & financial services; industrial; retail, consumer & leisure; and technology.
It counts close to 50 healthcare investments since 1990, betting on a range of companies around the world. Its pharma portfolio features CRO Syneos Health, generic makers Zentiva (Czech Republic) and Grupo Farmaceutico Somar (Mexico), India’s Bharat Serums and Vaccines, and Chinese capsule developer GS Capsule.
In recent years, though, Advent has made attempts to play a more direct role in drug development, including an ill-fated $8 billion
deal
to take rare disease player Sobi private and rumored
talks
with GSK about its consumer health spinout.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。